Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to Acquire Labor Dr. Merk& Kollegen to Strengthen its Next Generation Cancer Immunology ProgramBoehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk& KollegenTransaction expands Boehringer Ingelheim ’s R&D and clinical manufacturing capabilities with a site focused predominantly on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatmentsBoehringer Ingelheim aims to accelerate the delivery of first-in-class immuno-oncology therapies to patients around the world  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news